Serum Wisteria floribunda agglutinin-positive Mac-2-binding protein level predicts liver fibrosis and prognosis in primary biliary cirrhosis

American Journal of Gastroenterology

Volumn 110, Issue 6, 2015, Pages 857-864

  Umemura, Takeji ^a   Joshita, Satoru ^a   Sekiguchi, Tomohiro ^a   Usami, Yoko ^b   Shibata, Soichiro ^a   Kimura, Takefumi ^a   Komatsu, Michiharu ^a   Matsumoto, Akihiro ^a   Ota, Masao ^a   Tanaka, Eiji ^a  

^a SHINSHU UNIVERSITY   (Japan)

^b SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

AGGLUTININ; BINDING PROTEIN; MAC 2 BINDING PROTEIN; UNCLASSIFIED DRUG; CHOLAGOGUE; MEMBRANE PROTEIN; N ACETYLGLUCOSAMINE RECEPTOR; PLANT LECTIN; TAA90K PROTEIN, HUMAN; TUMOR ANTIGEN; URSODEOXYCHOLIC ACID; WISTERIA LECTIN;

ADULT; AGGLUTININ POSITIVE MAC 2 BINDING PROTEIN ASSAY; ARTICLE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; DISEASE COURSE; FEMALE; HUMAN; HUMAN TISSUE; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; RECEIVER OPERATING CHARACTERISTIC; SEROLOGY; BLOOD; CASE CONTROL STUDY; COHORT ANALYSIS; COMPLICATION; DIAGNOSTIC USE; LIVER CIRRHOSIS, BILIARY; MIDDLE AGED; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY;

ANTIGENS, NEOPLASM; CASE-CONTROL STUDIES; CHOLAGOGUES AND CHOLERETICS; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER CIRRHOSIS, BILIARY; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; PLANT LECTINS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RECEPTORS, N-ACETYLGLUCOSAMINE; RETROSPECTIVE STUDIES; URSODEOXYCHOLIC ACID;

EID: 84930761959     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1038/ajg.2015.118     Document Type: Article

References (40)

1. Kaplan MM, Gershwin ME. Primary biliary cirrhosis. N Engl J Med 2005;353: 1261-73.
2. Selmi C, Bowlus CL, Gershwin ME et al. Primary biliary cirrhosis. Lancet 2011;377: 1600-9.
3. Lindor KD, Gershwin ME, Poupon R et al. Primary biliary cirrhosis. Hepatology 2009;50: 291-308.
4. Cadranel JF, Rufat P, Degos F. Practices of liver biopsy in France: results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000;32: 477-81.
5. Bravo AA, Sheth SG, Chopra S. Liver biopsy. N Engl J Med 2001;344: 495-500.
6. Zein CO, Angulo P, Lindor KD. When is liver biopsy needed in the diagnosis of primary biliary cirrhosis? Clin Gastroenterol Hepatol 2003;1: 89-95.
7. Kuno A, Ikehara Y, Tanaka Y et al. A serum "sweet-doughnut" protein facilitates fi brosis evaluation and therapy assessment in patients with viral hepatitis. Sci Rep 2013;3: 1065.
8. Sasaki T, Brakebusch C, Engel J et al. Mac-2 binding protein is a cell-adhesive protein of the extracellular matrix which self-assembles into ring-like structures and binds beta1 integrins, collagens and fi bronectin. EMBO J 1998;17: 1606-13.
9. Inohara H, Akahani S, Koths K et al. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996;56: 4530-4.
10. Toshima T, Shirabe K, Ikegami T et al. A novel serum marker, glycosylated Wisteria fl oribunda agglutinin-positive Mac-2 binding protein (WFAM2BP), for assessing liver fi brosis. J Gastroenterol 2014;50: 76-84.
11. Abe M, Miyake T, Kuno A et al. Association between Wisteria floribunda agglutinin-positive Mac-2 binding protein and the fi brosis stage of nonalcoholic fatty liver disease. J Gastroenterol 2014 (in press).
12. Yamasaki K, Tateyama M, Abiru S et al. Elevated serum levels of WFA-M2BP predict the development of hepatocellular carcinoma in hepatitis C patients. Hepatology 2014;60: 1563-70.
13. Wai CT, Greenson JK, Fontana RJ et al. A simple noninvasive index can predict both significant fi brosis and cirrhosis in patients with chronic hepatitis C. Hepatology 2003;38: 518-26.
14. Sterling RK, Lissen E, Clumeck N et al. Development of a simple noninvasive index to predict significant fi brosis in patients with HIV/HCV coinfection. Hepatology 2006;43: 1317-25.
15. Forns X, Ampurdanes S, Llovet JM et al. Identification of chronic hepatitis C patients without hepatic fi brosis by a simple predictive model. Hepatology 2002;36: 986-92.
16. Dickson ER, Grambsch PM, Fleming TR et al. Prognosis in primary biliary cirrhosis: model for decision making. Hepatology 1989;10: 1-7.
17. Umemura T, Katsuyama Y, Yoshizawa K et al. Human leukocyte antigen class II haplotypes aff ect clinical characteristics and progression of type 1 autoimmune hepatitis in Japan. PLoS ONE 2014;9: e100565.
18. Umemura T, Zen Y, Hamano H et al. Immunoglobin G4-hepatopathy: association of immunoglobin G4-bearing plasma cells in liver with autoimmune pancreatitis. Hepatology 2007;46: 463-71.
19. Scheuer P. Primary biliary cirrhosis. Proc R Soc Med 1967;60: 1257-60.
20. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology 1996;24: 289-93.
21. Hiramatsu K, Aoyama H, Zen Y et al. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology 2006;49: 466-78.
22. Kuno A, Sato T, Shimazaki H et al. Reconstruction of a robust glycodiagnostic agent supported by multiple lectin-assisted glycan profi ling. Proteomics Clin Appl 2013;7: 642-7.
23. DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach. Biometrics 1988;44: 837-45.
24. Farkkila M, Rautiainen H, Karkkainen P et al. Serological markers for monitoring disease progression in noncirrhotic primary biliary cirrhosis on ursodeoxycholic acid therapy. Liver Int 2008;28: 787-97.
25. Alempijevic T, Krstic M, Jesic R et al. Biochemical markers for noninvasive assessment of disease stage in patients with primary biliary cirrhosis. World J Gastroenterol 2009;15: 591-4.
26. Mayo MJ, Parkes J, Adams-Huet B et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008;48: 1549-57.
27. Corpechot C, El Naggar A, Poujol-Robert A et al. Assessment of biliary fibrosis by transient elastography in patients with PBC and PSC. Hepatology 2006;43: 1118-24.
28. Gomez-Dominguez E, Mendoza J, Garcia-Buey L et al. Transient elastography to assess hepatic fibrosis in primary biliary cirrhosis. Aliment Pharmacol Ther 2008;27: 441-7.
29. Corpechot C, Carrat F, Poujol-Robert A et al. Noninvasive elastographybased assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012;56: 198-208
30. Castera L, Foucher J, Bernard PH et al. Pitfalls of liver stiff ness measurement: a 5-year prospective study of 13, 369 examinations. Hepatology 2010;51: 828-35.
31. Nakamura M, Kondo H, Mori T et al. Anti-gp210 and anti-centromere antibodies are diff erent risk factors for the progression of primary biliary cirrhosis. Hepatology 2007;45: 118-27.
32. Umemura T, Joshita S, Ichijo T et al. Human leukocyte antigen class II molecules confer both susceptibility and progression in Japanese patients with primary biliary cirrhosis. Hepatology 2012;55: 506-11.
33. Lammers WJ, van Buuren HR, Hirschfield GM et al. Levels of alkaline phosphatase and bilirubin are surrogate endpoints of outcomes of patients with primary biliary cirrhosis-an international follow-up study. Gastroenterology 2014;147: 1338-49.
34. Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology 2006;130: 715-20.
35. Corpechot C, Abenavoli L, Rabahi N et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008;48: 871-7.
36. Kuiper EM, Hansen BE, de Vries RA et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009;136: 1281-7.
37. Kumagi T, Guindi M, Fischer SE et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010;105: 2186-94.
38. Corpechot C, Chazouilleres O, Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011;55: 1361-7.
39. Trivedi PJ, Bruns T, Cheung A et al. Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. J Hepatol 2014;60: 1249-58.
40. Zhang LN, Shi TY, Shi XH et al. Early biochemical response to ursodeoxycholic acid and long-term prognosis of primary biliary cirrhosis: results of a 14-year cohort study. Hepatology 2013;58: 264-72.